Skip to main content
SpringerLink
Log in

Gynecologic Cancers

  • Chapter
Book cover Geriatric Medicine

  • 566 Accesses

Summary

As with other malignancies, gynecologic cancers are best managed if they are detected and treated early. Tumor biology varies substantially for each of the cancers reviewed. Stage for stage, elderly patients tend to have poorer survival rates than their younger cohorts. Appropriate attention to detail during annual or problem-related examinations and diligence in following screening protocols should allow prompt diagnosis. Age does not preclude aggressive management of cancer. Referral to a gynecologic oncologist is important if the patient is to receive the benefit of the most effective therapy and the option of participation in randomized research protocols involving novel treatments. Hormone replacement therapy, sexuality, and other quality of life issues should be considered when caring for individuals with gynecologic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK: SEER Cancer Statistics Review, 1973–1999, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1973_1999/,2002.

    Google Scholar 

  2. Ries LAG, Hankey BF, Miller BA, et al. Cancer Statistics Review. NIH pub 91-2789. Bethesda, MD: National Cancer Institute, 1991.

    Google Scholar 

  3. Edwards BK, Howe HL, Ries LA, Thun MJ, et al. Annual report to the nation on the status of cancer, 1973–1999: featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–2792.

    Article  PubMed  Google Scholar 

  4. Parazzini F, La Veccia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol. 1991;41:1–16.

    Article  PubMed  CAS  Google Scholar 

  5. Gambrell RDJ, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer. Am J Obstet Gynecol 1983;146:696–707.

    PubMed  CAS  Google Scholar 

  6. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinom a. N Engl J Med. 1975;293:1164–1167.

    Article  PubMed  CAS  Google Scholar 

  7. Seoud MA, Johnson J, Weed JCJ. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993;82:165–169.

    PubMed  CAS  Google Scholar 

  8. Quinn MA, Cauchi M, Fortune D. Endometrial carcinom a: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol. 1985;21:314–319.

    Article  PubMed  CAS  Google Scholar 

  9. Centers for Disease Control. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA. 1983; 249:1600–1604.

    Article  Google Scholar 

  10. Lawrence C, Tessaro I, Durgerian S, et al. Smoking, body weight, and early-stage endometrial cancer. Cancer. 1987; 59:1665–1669.

    PubMed  CAS  Google Scholar 

  11. Smith EM, Anderson B. Symptomatology, delay, and stage of disease in endometrial cancer. Cancer Detect Prev. 1987; 10:247–254.

    PubMed  CAS  Google Scholar 

  12. Walters D, Robinson D, Park RC, et al. Diagnostic out-patient aspiration curettage. Obstet Gynecol. 1975;46: 160–164.

    PubMed  CAS  Google Scholar 

  13. Tsuda H, Kawabata M, Yamamoto K, et al. Prospective study to compare endometrial cytology and transvaginal 1 ultrasonography for identification of endometrial malignancies. Gynecol Oncol. 1997;65:383–386.

    Article  PubMed  CAS  Google Scholar 

  14. Cohen I, Beyth Y, Tepper R. The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. Obstet Gynecol Surv. 1998;53:429–438.

    Article  PubMed  CAS  Google Scholar 

  15. Hall KL, Dewar MA, Perchalski J. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms. Prim Care. 1992;19:607–620.

    PubMed  CAS  Google Scholar 

  16. Creasman WT, Morrow PC, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60: 2035–2041.

    PubMed  CAS  Google Scholar 

  17. Sant CL, Weppelmann B, Shingleton H, et al. Management of early endometrial carcinoma. Gynecol Oncol. 1989; 35:362–366.

    Article  Google Scholar 

  18. Cowles TA, Magrina JF, Masterson BJ, et al. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol. 1985;66:413–416.

    PubMed  CAS  Google Scholar 

  19. Sutton GP, Geisler HE, Stehman FB, et al. Features associated with survival and disease-free survival in early endometrial cancer. Am J Obstet Gynecol. 1989;160:1385–1391.

    PubMed  CAS  Google Scholar 

  20. Palmer DC, Muir IM, Alexander AI, et al. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol. 1988;72:388–393.

    PubMed  CAS  Google Scholar 

  21. Roberts JA, Brunetto VL, Keys HM, et al. A phase III randomized study of surgery versus surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma (GOG 99). Presented at Society of Gynecologic Oncologists, 28th Annual Meeting, Orlando, FL, 1998.

    Google Scholar 

  22. Soper JT, Creasman WT, Clarke-Pearson DL, et al. Intraperitoneal chromic phosphate P32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985;153:191–196.

    PubMed  CAS  Google Scholar 

  23. Martinez A, Podratz K, Schray M, et al. Results of whole abdominopelvic irradiation with nodal boost for patients with endometrial cancer at high risk of failure in the peritoneal cavity. A prospective clinical trial at the Mayo Clinic. Hematol Oncol Clin North Am. 1988;2:431–446.

    PubMed  CAS  Google Scholar 

  24. Potish RA, Twiggs LB, Adcock LL, et al. Paraaortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol. 1985;65:251–256.

    PubMed  CAS  Google Scholar 

  25. Martinez A, Schray M, Podratz K, et al. Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys. 1989; 17:371–377.

    PubMed  CAS  Google Scholar 

  26. Ahmad K, Kim YH, Deppe G, et al. Results of treatment in locally advanced carcinoma of the endometrium. Acta Oncol. 1990;29:203–209.

    PubMed  CAS  Google Scholar 

  27. Bonte J, Ide P, Billiet G, et al. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Qncol. 1981;11:140–161.

    Article  CAS  Google Scholar 

  28. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol. 1989;28:561–566.

    PubMed  CAS  Google Scholar 

  29. Thigpen T, Vance RB, Balducci L, et al. Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer. 1981;48:658–665.

    PubMed  CAS  Google Scholar 

  30. Price FV, Edwards RP, Kelley JL, et al. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol. 1997;24:S15–S15.

    PubMed  CAS  Google Scholar 

  31. Kosary CI. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994; 10:31–46.

    PubMed  CAS  Google Scholar 

  32. Olt G, Berchuck A, Bast RC Jr. The role of tumor markers in gynecologic oncology. Obstet Gynecol Surv. 1990;45: 570–577.

    PubMed  CAS  Google Scholar 

  33. Creasman WT. Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. Oncology. 1992;6:23–26.

    PubMed  CAS  Google Scholar 

  34. Ozols RF, Rubin SC, Thomas GM, et al. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology, 2nd Ed. Philadelphia: Lippincott-Raven; 1996:919–986.

    Google Scholar 

  35. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993;71:517–523.

    Article  PubMed  CAS  Google Scholar 

  36. Heintz APM, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol. 1985;66:127–135.

    PubMed  CAS  Google Scholar 

  37. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331: 771–776.

    Article  PubMed  CAS  Google Scholar 

  38. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer. 1993; 71:582–588.

    PubMed  CAS  Google Scholar 

  39. Lynch HT, Watson P, Lynch JF, et al. Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer. 1993;71: 573–581.

    Article  PubMed  CAS  Google Scholar 

  40. Kurman RJ. Blaustein’s Pathology of the Female Genital Tract, 4th Ed. New York: Springer-Verlag; 1994.

    Google Scholar 

  41. Goff BA, Mandel LS, Muntz HG, et al. Ovarian cancer diagnosis: results of a national cancer survey. Presented at Society of Gynecologic Oncologists, 31st Annual Meeting, San Diego, CA 2000.

    Google Scholar 

  42. Podczaski E, Whitney C, Manetta A, et al. Use of CA 125 to monitor patients with ovarian epithelial carcinomas. Gynecol Oncol. 1989;33:193–197.

    Article  PubMed  CAS  Google Scholar 

  43. McGowan L. Patterns of care in carcinoma of the ovary. Cancer. 1993;71:628–633.

    Article  PubMed  CAS  Google Scholar 

  44. Clarke-Pearson DL, DeLong ER, Chin N, et al. Intestinal obstruction in patients with ovarian cancer: variables associated with surgical complications and survival. Arch Surg. 1988;123:42–45.

    PubMed  CAS  Google Scholar 

  45. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–287.

    Article  PubMed  CAS  Google Scholar 

  46. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

    Article  PubMed  CAS  Google Scholar 

  47. Ozols RF, Bundy BN, Fowler JM, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial. Presented at Society of Gynecologic Oncologists, 31st Annual Meeting, San Diego, CA 2000.

    Google Scholar 

  48. Ozols RF, Young RC. Ovarian cancer. Curr Probl Cancer. 1987;11:57–122.

    PubMed  CAS  Google Scholar 

  49. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol. 1994;12:2121–2125.

    PubMed  CAS  Google Scholar 

  50. Alberts DS, Dahlberg S, Green SJ, et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993;71:618–627.

    Article  PubMed  CAS  Google Scholar 

  51. Bicher A, Sarosy G, Kohn E, et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 1993;71:594–600.

    Article  PubMed  CAS  Google Scholar 

  52. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995;6:887–893.

    PubMed  CAS  Google Scholar 

  53. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer. 1985;55:2285–2290.

    PubMed  CAS  Google Scholar 

  54. Trimble EL, Kosary CL, Cornelison TL, et al. Temporal trends in ovarian cancer survival. Presented at Society of Gynecologic Oncologists, 30th Annual Meeting, San Francisco, CA 1999.

    Google Scholar 

  55. Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer. 1993;71:524–529.

    Article  PubMed  CAS  Google Scholar 

  56. Gershenson DM, Mitchell MF, Atkinson N, et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer. 1993;71:638–643.

    Article  PubMed  CAS  Google Scholar 

  57. Steiner M, Rubinov R, Borovik R, et al. Multimodal approach (surgery, chemotherapy, and radiotherapy) in the treatment of advanced ovarian carcinoma. Cancer. 1985;55: 2748–2752.

    PubMed  CAS  Google Scholar 

  58. Marchetti DL, Lele SB, Priore RL, et al. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol. 1993;49:86–91.

    Article  PubMed  CAS  Google Scholar 

  59. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580–1584.

    PubMed  CAS  Google Scholar 

  60. Podczaski ES, Stevens CWJ, Manetta A, et al. Use of second-look laparotomy in the management of patients with ovarian epithelial malignancies. Gynecol Oncol. 1987; 28:205–214.

    Article  PubMed  CAS  Google Scholar 

  61. Potter ME. Secondary cytoreduction in ovarian cancer: pro or con? Gynecol Oncol. 1993;51:131–135.

    Article  PubMed  CAS  Google Scholar 

  62. Friedman JB, Weiss NS. Second thoughts about secondlook laparotomy in advanced ovarian cancer. N Engl J Med. 1990;322:1079–1082.

    Article  PubMed  CAS  Google Scholar 

  63. Hightower RD, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer. 1994;73:377–383.

    PubMed  CAS  Google Scholar 

  64. Sutton GP, Stehman FB, Einhorn LH, et al. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol. 1989;51:301–306.

    Google Scholar 

  65. Brinton LA, Herrero R, Reeves WC, et al. Risk factors for cervical cancer by histology. Gynecol Oncol. 1993;51:301–306.

    Article  PubMed  CAS  Google Scholar 

  66. Vermund SH, Kelley KF, Klein RS, et al. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol. 1991;165:392–400.

    PubMed  CAS  Google Scholar 

  67. Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst. 1987;79:23–30.

    PubMed  CAS  Google Scholar 

  68. La Vecchia C, Decarli A, Fasoli M, et al. Dietary vitamin A and the risk of intraepithelial and invasive cervical neoplasia. Gynecol Oncol. 1988;30:187–195.

    Article  PubMed  Google Scholar 

  69. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners’ Oral Contraception Study. Lancet. 1988;2:1331–1335.

    Article  PubMed  CAS  Google Scholar 

  70. Reeves WC, Rawls WE, Brinton LA. Epidemiology of genital papillomaviruses and cervical cancer. Rev Infect Dis. 1989;11:426–439.

    PubMed  CAS  Google Scholar 

  71. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol. 1983;27:220–224.

    PubMed  CAS  Google Scholar 

  72. Benedet JL, Anderson GH, Matisic JP. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol. 1992;166:1254–1259.

    PubMed  CAS  Google Scholar 

  73. Runowicz CD, Goldberg GL, Smith HO. Cancer screening for women older than 40 years of age. Obstet Gynecol Clin North Am. 1993;20:391–408.

    PubMed  CAS  Google Scholar 

  74. Gostout BS, Podratz KC, McGovern RM, et al. Cervical cancer in older women: a molecular analysis of human papillomavirus types, HLA types, and p53 mutations. Am J Obstet Gynecol. 1998;179:56–61.

    Article  PubMed  CAS  Google Scholar 

  75. Taylor RR, Teneriello MG, Nash JD, et al. The molecular genetics of gyn malignancies. Oncology. 1994;8:63–70.

    PubMed  CAS  Google Scholar 

  76. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology, 5th Ed. St. Louis: Mosby; 1997.

    Google Scholar 

  77. DiSaia PJ. Surgical aspects of cervical carcinoma. Cancer. 1981;48:548–559.

    PubMed  CAS  Google Scholar 

  78. Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67:2776–2785.

    PubMed  CAS  Google Scholar 

  79. Brookland RK, Rubin S, Danoff BF. Extended field irradiation in the treatment of patients with cervical carcinoma involving biopsy proven para-aortic nodes. Int J Radiat Oncol Biol Phys. 1984;10:1875–1879.

    PubMed  CAS  Google Scholar 

  80. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–1161.

    Article  PubMed  CAS  Google Scholar 

  81. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153.

    Article  PubMed  CAS  Google Scholar 

  82. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–1348.

    PubMed  CAS  Google Scholar 

  83. Magrina JF. Complications of irradiation and radical surgery for gynecologic malignancies. Obstet Gynecol Surv. 1993;48:571–575.

    PubMed  CAS  Google Scholar 

  84. Fuchtner C, Manetta A, Walker JL, et al. Radical hysterectomy in the elderly patient: analysis of morbidity. Am J Obstet Gynecol. 1992;166:593–597.

    PubMed  CAS  Google Scholar 

  85. Geisler JP, Geisler HE. Radical hysterectomy in patients 65 years of age and older. Gynecol Oncol. 1994;53:208–211.

    Article  PubMed  CAS  Google Scholar 

  86. Hopkins MP, Morley GW. Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer. 1991;68:272–277.

    PubMed  CAS  Google Scholar 

  87. Carter J, Ramirez C, Waugh R, et al. Percutaneous urinary diversion in gynecologic oncology. Gynecol Oncol. 1991; 40:248–252.

    Article  PubMed  CAS  Google Scholar 

  88. Sorbe B, Frankendal B. Bleomycin-adriamycin-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent cervical carcinoma. Obstet Gynecol. 1984;63:167–170.

    PubMed  CAS  Google Scholar 

  89. Giannone L, Brenner DE, Jones HW, et al. Combination chemotherapy for patients with advanced carcinoma of the cervix: trial of mitomycin-C, vincristine, bleomycin, and cisplatin. Gynecol Oncol. 1987;26:178–182.

    Article  PubMed  CAS  Google Scholar 

  90. Morley GW, Hopkins MP. Pelvic exenteration. In: Thompson JD, Rock JA, eds. Te Linde’s Operative Gynecology, 7th Ed. Philadelphia: Lippincott; 1992:1329–1345.

    Google Scholar 

  91. Kodama S, Kanazawa K, Honma S, et al. Age as a prognostic factor in patients with squamous cell carcinoma of the uterine cervix. Cancer. 1991;68:2481–2485.

    PubMed  CAS  Google Scholar 

  92. Chapman GW. Patterns of cervical carcinoma in women of advanced age. J Natl Med Assoc. 1997;89:801–804.

    PubMed  Google Scholar 

  93. Jolles CJ, Freedman RS, Hamberger AD, et al. Complications of extended-field therapy for cervical carcinoma without prior surgery. Int J Radiat Oncol Biol Phys. 1986; 12:179–183.

    PubMed  CAS  Google Scholar 

  94. Brinton LA, Nasca PC, Mallin K, et al. Case-control study of cancer of the vulva. Obstet Gynecol. 1990;75:859–866.

    PubMed  CAS  Google Scholar 

  95. Rusk D, Sutton GP, Look KY, et al. Analysis of invasive squamous cell carcinoma of the vulva and vulvar intraepithelial neoplasia for the presence of human papillomavirus DNA. Obstet Gynecol. 1991;77:918–922.

    PubMed  CAS  Google Scholar 

  96. Stehman FB, Bundy BN, Dvoretsky PM, et al. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992;79:490–497.

    PubMed  CAS  Google Scholar 

  97. Berek JS, Heaps JM, Fu YS, et al. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol. 1991;42:197–201.

    Article  PubMed  CAS  Google Scholar 

  98. Hopkins MP, Morley GW. Pelvic exenteration for the treatment of vulvar cancer. Cancer. 1992;70:2835–2838.

    PubMed  CAS  Google Scholar 

  99. Farias-Eisner R, Berek JS. Current management of invasive squamous carcinoma of the vulva. Clin Geriatr Med. 1993;9:131–143.

    PubMed  CAS  Google Scholar 

  100. Lawton FG, Hacker NF. Surgery for invasive gynecologic cancer in the elderly female population. Obstet Gynecol. 1990;76:287–289.

    PubMed  CAS  Google Scholar 

  101. Piura B, Masotina A, Murdoch J, et al. Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol. 1993;48:189–195.

    Article  PubMed  CAS  Google Scholar 

  102. Power EJ. Pap smears, elderly women, and Medicare. Cancer Investig. 1993;11:164–168.

    CAS  Google Scholar 

  103. List ND, Kucuk O. Approaches to and effectiveness of current cancer interventions in the elderly. Oncology. 1992;6: 31–38.

    PubMed  CAS  Google Scholar 

  104. McGonigle KF, Lagasse LD, Karlan BY. Ovarian, uterine, and cervical cancer in the elderly woman. Clin Geriatr Med. 1993;9:115–130.

    PubMed  CAS  Google Scholar 

  105. McKenna RJS. Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up. Cancer. 1994;74:2107–2117.

    PubMed  Google Scholar 

  106. Ganz PA. Does (or should) chronologic age influence the choice of cancer treatment? Oncology. 1992;6:45–49.

    PubMed  CAS  Google Scholar 

  107. Ganz PA. Age and gender as factors in cancer therapy. Clin Geriatr Med. 1993;9:145–155.

    PubMed  CAS  Google Scholar 

  108. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK. SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: National Cancer Institute; 1999.

    Google Scholar 

Download references

Authors
  1. Angeles A. Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel L. Clarke-Pearson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Alvarez, A.A., Clarke-Pearson, D.L. (2003). Gynecologic Cancers. In: Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/0-387-22621-4_38

Download citation

  • DOI: https://doi.org/10.1007/0-387-22621-4_38

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95514-8

  • Online ISBN: 978-0-387-22621-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation